GSK Investigator-sponsored studies programme





Notification to all users:

For HIV-specific proposals, please contact your ViiV Healthcare representative.

We are dedicated to improving the quality of human life by enabling people to do more, feel better and live longer. As part of this commitment, we recognise the valuable role that our support of investigator-sponsored studies (ISS) plays in fulfilling this mission. An investigator-sponsored study is a research effort where the sponsor of the work is an investigator, healthcare institution, or some form of medical network external to GSK and is seeking our support to conduct the work. This support can be in the form of product, funding, or a combination of both.

We only support ISS that have a legitimate scientific purpose. The decision to support a study proposal is based on the importance of the research objectives to medical science or patient care, the scientific rationale for the proposed methodology, and the ability of the study sponsor to deliver a high-quality ethical study.

We do not support ISS in order to reward healthcare professionals for using, purchasing, recommending, or prescribing GSK products or to persuade them to do so by supporting the proposed research.

GSK’s policy is that human subject research results be made public. Therefore, as a condition of support the sponsor must provide a Public Disclosure Plan (PDP) as requested in the submission form. This should include details around publications and postings to a worldwide public register for all human subject research.

Any failure by the sponsor to meet the public disclosure commitments as detailed in PDP and legal agreement will be taken into consideration when reviewing any subsequent proposals submitted by the sponsor and may result in a decision by GSK not to support the proposal.

In order to fully utilise this site, you must first register a profile. Once registered, you will be able to:

  1. Submit study proposals directly into GSK’s ISS system, which will facilitate more timely reviews and decisions
  2. Check on the status of both proposals and previously approved active studies
  3. Post and receive electronic documentation directly through the system
  4. Receive periodic prompts regarding key milestones and deliverables associated with your proposals or previously approved studies

User guidance


Click here to view browser requirements for this portal.


Terms of use Accessibility Cookie policy Privacy
© 2001-2017 GlaxoSmithKline plc. All rights reserved. Registered in England and Wales No. 3888792.
Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.